Tiziana Life Sciences
  • Our Company
    • Our Company
    • About us
    • Our Team
  • Technology
  • Pipeline
    • Intranasal Foralumab
      • Secondary Progressive Multiple Sclerosis
      • Alzheimer’s Disease
      • Other Indications
    • Anti IL-6R (TZLS-501)
    • Milciclib (TZLS-201)
  • Investors, News & Media
    • News
    • Media
    • Publications
    • Investors
  • Contact
Select Page
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

by Paul | 14 August 2024 | News

NEW YORK, August 14, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Recent Posts

  • Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
  • Tiziana Life Sciences to Present at the Bio International Convention
  • Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
  • Interview Aired Nationwide Highlighting Intranasal Foralumab Treating Moderate Alzheimer’s Disease
  • Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer’s Disease  

Recent Comments

No comments to show.

Tiziana Life Sciences, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda  |  info@tizianalifesciences.com   |  +44 (0) 207 495 2379

  • Follow
  • Follow

© Tiziana Life Sciences 2025  |   Legal  |  Privacy Policy

NASDAQ: TLSA